Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI Agreement#Y1-CN-2017-04 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study, we will evaluate the effectiveness of several doses of oral selenomethionine in raising biomarkers of selenium status including plasma selenium concentrations.
Results of studies with animal tumor models and human clinical trials suggest that the essential nutrient selenium can be anti-tumorigenic if consumed at levels greater than nutritional requirements. If it is possible to increase plasma selenium concentrations above 120 nanograms per milliliter with less than 200 micrograms of selenium daily, then it is possible that supplementation can be accomplished through the use of selenium-containing foods.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Capsule contains no selenium |
|
| Selenium as L-selenomethionine | Active Comparator | 50, 100, or 200 micrograms of selenium |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| placebo | Dietary Supplement | daily placebo capsules for 12 months |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of effectiveness of consuming oral doses of L-selenomethionine in raising plasma selenium concentrations | Baseline, and after 3, 6, 9, and 12 months of supplementation |
| Measure | Description | Time Frame |
|---|---|---|
| Biomarkers of selenium status will be determined in urine, buccal cells, and plasma. White blood cells will be analyzed to identify DNA damage, reflecting the degree of oxidative damage and evaluate the status of antioxidant repair mechanisms. | Baseline and after 12 months of supplementation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gerald F Combs, PhD | USDA Grand Forks Human Nutrition Research Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| USDA Grand Forks Human Nutrition Research Center | Grand Forks | North Dakota | 58202 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 18827575 | Background | Jackson MI, Combs GF Jr. Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care. 2008 Nov;11(6):718-26. doi: 10.1097/MCO.0b013e3283139674. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012643 | Selenium |
| ID | Term |
|---|---|
| D018011 | Chalcogens |
| D004602 | Elements |
| D007287 | Inorganic Chemicals |
| D008903 | Minerals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| selenium as L-selenomethionine |
| Dietary Supplement |
daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months |
|